Globenewswireยท2025-03-25 08:15Core Insights - Royal Philips was the leading applicant in medical technology at the European Patent Office in 2024, filing 594 Medtech patent applications, highlighting its commitment to healthcare transformation through informatics and AI [3][7] - The company aims to improve the health and well-being of 2.5 billion people by 2030, having already improved the lives of nearly 2 billion people in 2024 [5] - Philips invested approximately EUR 1.7 billion in R&D in 2024, representing over 9% of sales, which is significantly above the industry average [9] Innovation and Technology - Philips launched several informatics and AI-powered innovations in 2024, including the Azurion image-guided therapy system and FDA-cleared AI tools for cardiovascular imaging [12] - The company has a robust intellectual property portfolio with 50,500 patent rights, 30,500 trademarks, and 150,000 design rights, reinforcing its innovation leadership [9] - Philips was included in the Clarivate Top 100 Global Innovators 2025, marking its 12th consecutive year in this assessment [8] Market Position - Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,800 people, with operations in over 100 countries [10] - The company maintains its 1 global position in cardiovascular ultrasound, supported by advancements in automation and productivity [12]